Drainage of thoracic duct lymph in twelve patients with myasthenia gravis.
The effect of thoracic duct lymph drainage (5-34 days) in 12 patients with myasthenia gravis on muscular function has been followed for 5-43 months. Among the results obtained were: (1) During the drainage the myasthenic symptoms decreased markedly after 1-4 days and remained so during the drainage. (2) The doses of cholinesterase inhibitors had to be markedly reduced during the lymph drainage in eight patients. (3) Discontinuation of the lymph drainage increased the myasthenic symptoms within a few days. However, after a median observation time of 14 months with conventional treatment all but one of the patients had improved. (4) Retransfusion of the patients own cell-free lymph caused a worsening of the myasthenic symptoms. This effect could also be obtained following infusion of IgG preparations from the patients lymph. Three retransfusions of cell suspensions obtained from the thoracic duct lymph from two patients had no effects on their myasthenic symptoms. (5) It is suggested that thoracic duct lymph drainage can be combined with other forms of treatment in severe cases of myasthenia gravis.
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004322:Drainage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use; D008196:Lymph; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000628:therapy*; D013897:Thoracic Duct / Q000601:surgery*; D013997:Time Factors
D002800:Cholinesterase Inhibitors; D007074:Immunoglobulin G; D000324:Adrenocorticotropic Hormone; D001379:Azathioprine